These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8201244)

  • 1. The breadth of action of the 5-HT3 receptor antagonists.
    Costall B
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():3-9. PubMed ID: 8201244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin and psychiatric disorders. A key to new therapeutic approaches.
    Costall B; Naylor RJ
    Arzneimittelforschung; 1992 Feb; 42(2A):246-9. PubMed ID: 1586395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astra Award Lecture. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Dec; 71(6):401-15. PubMed ID: 1362267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin receptor subtypes: implications for psychopharmacology.
    Cowen PJ
    Br J Psychiatry Suppl; 1991 Sep; (12):7-14. PubMed ID: 1840764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological properties and functions of central 5-HT3 receptors.
    Costall B; Naylor RJ
    Therapie; 1991; 46(6):437-44. PubMed ID: 1840228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ondansetron--the first highly selective 5-HT3 antagonist in therapy of psychiatric diseases].
    Broocks A
    Fortschr Neurol Psychiatr; 1992 Jun; 60(6):227-36. PubMed ID: 1386589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical utility of pharmacological agents that act at serotonin receptors.
    Peroutka SJ; Sleight AJ; McCarthy BG; Pierce PA; Schmidt AW; Hekmatpanah CR
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):253-62. PubMed ID: 2562495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin receptors--where are they going?
    Leonard BE
    Int Clin Psychopharmacol; 1994 Mar; 9 Suppl 1():7-17. PubMed ID: 8021439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic mechanisms and current and future psychiatric practice.
    Dubovsky SL; Thomas M
    J Clin Psychiatry; 1995; 56 Suppl 2():38-48. PubMed ID: 7844106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain serotonin subsystem complexity and receptor heterogeneity: therapeutic potential of selective serotonin agonists and antagonists.
    Lesch KP; Aulakh CS; Murphy DL
    Psychopharmacol Ser; 1993; 10():52-69. PubMed ID: 8361982
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple serotonin receptors: clinical and experimental aspects.
    Roth BL
    Ann Clin Psychiatry; 1994 Jun; 6(2):67-78. PubMed ID: 7804391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anxiolytic potential of 5-HT3 receptor antagonists.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Mar; 70(3):157-62. PubMed ID: 1349746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential.
    Greenshaw AJ
    Trends Pharmacol Sci; 1993 Jul; 14(7):265-70. PubMed ID: 8105596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction.
    Dubovsky SL; Thomas M
    J Psychosom Res; 1995 May; 39(4):429-44. PubMed ID: 7562673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonin receptor and reuptake sites: pharmacologic significance.
    Gonzalez-Heydrich J; Peroutka SJ
    J Clin Psychiatry; 1990 Apr; 51 Suppl():5-12; discussion 13. PubMed ID: 2157701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pros and cons of 5-HT
    Rahimian R; Fakhfouri G; Zirak MR
    Biomed Pharmacother; 2019 Oct; 118():109301. PubMed ID: 31402188
    [No Abstract]   [Full Text] [Related]  

  • 18. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
    Guise S; Soubrouillard C; Blin O
    Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta blockers in psychiatric illness.
    Drug Ther Bull; 1974 Jul; 12(14):54-5. PubMed ID: 4156514
    [No Abstract]   [Full Text] [Related]  

  • 20. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.
    Greenshaw AJ; Silverstone PH
    Drugs; 1997 Jan; 53(1):20-39. PubMed ID: 9010647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.